Patents by Inventor Zhenhua Miao

Zhenhua Miao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATION THERAPY USING A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1/PD-L1 INHIBITOR
    Publication number: 20230263784
    Abstract: The present disclosure is drawn to the combination therapy of a Chemokine Receptor 2 (CCR2) antagonist and a PD-1 and/or PD-L1 inhibitor in the treatment of cancer.
    Type: Application
    Filed: February 6, 2023
    Publication date: August 24, 2023
    Inventors: James J. CAMPBELL, Zhenhua MIAO
  • COMBINATION THERAPY USING A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1/PD-L1 INHIBITOR
    Publication number: 20230023075
    Abstract: The present disclosure is drawn to the combination therapy of a Chemokine Receptor 2 (CCR2) antagonist and a PD-1 and/or PD-L1 inhibitor in the treatment of cancer.
    Type: Application
    Filed: March 15, 2022
    Publication date: January 26, 2023
    Inventors: James J. CAMPBELL, Zhenhua MIAO, Thomas J. SCHALL, Israel CHARO, Shijie LI, Christine Marie JANSON, Rajinder SINGH, Karen EBSWORTH
  • METHOD OF TREATING LIVER FIBROSIS
    Publication number: 20220313668
    Abstract: A method of treating liver fibrosis with CCR2 antagonists is provided. The liver fibrosis may be associated with non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), emerging cirrhosis, non-cirrhotic hepatic fibrosis, type 2 diabetes mellitus (T2DM) or metabolic syndrome (MS).
    Type: Application
    Filed: May 11, 2022
    Publication date: October 6, 2022
    Inventors: Zhenhua MIAO, Israel Charo
  • TREATMENT OF FOCAL SEGMENTAL GLOMERULOSCLEROSIS WITH CCR2 ANTAGONISTS
    Publication number: 20220296601
    Abstract: Provided herein are methods of treating focal segmental glomerulosclerosis, said methods include administering to a subject in need thereof a therapeutically effective amount of a CCR2 antagonist. In some embodiments, the CCR2 antagonist is used in monotherapy. In some embodiments, the CCR2 antagonist is used in combination therapy. In some embodiments, the additional therapeutic agent is a RAAS blocker and/or an endothelin receptor inhibitor.
    Type: Application
    Filed: June 3, 2022
    Publication date: September 22, 2022
    Inventors: Zhenhua MIAO, Thomas J. Schall, Rajinder Singh
  • METHOD OF TREATING FOCAL SEGMENTAL GLOMERULOSCLEROSIS
    Publication number: 20220226294
    Abstract: A method of treating focal segmental glomerulosclerosis with a compound of Formula I is provided. FSGS may be primary (no known cause) or secondary. The secondary FSGS may be associated with infections or viruses such as HIV, diseases such as sickle cell disease or lupus, toxins or drugs such as anabolic steroids, heroin or pamidronate, nephron loss and hyperfiltration, such as with chronic pyelonephritis and reflux, morbid obesity, or diabetes mellitus.
    Type: Application
    Filed: April 8, 2022
    Publication date: July 21, 2022
    Inventors: Zhenhua MIAO, Thomas SCHALL, Rajinder SINGH
  • Treatment of focal segmental glomerulosclerosis with CCR2 antagonists
    Patent number: 11382915
    Abstract: Provided herein are methods of treating focal segmental glomerulosclerosis, said methods include administering to a subject in need thereof a therapeutically effective amount of a CCR2 antagonist. In some embodiments, the CCR2 antagonist is used in monotherapy. In some embodiments, the CCR2 antagonist is used in combination therapy. In some embodiments, the additional therapeutic agent is a RAAS blocker and/or an endothelin receptor inhibitor. The CCR2 antagonist may have the structure of formula (I).
    Type: Grant
    Filed: August 11, 2020
    Date of Patent: July 12, 2022
    Assignee: ChemoCentryx, Inc.
    Inventors: Zhenhua Miao, Thomas J. Schall, Rajinder Singh
  • Method of treating liver fibrosis
    Patent number: 11357760
    Abstract: A method of treating liver fibrosis with CCR2 antagonists is provided. The liver fibrosis may be associated with non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), emerging cirrhosis, non-cirrhotic hepatic fibrosis, type 2 diabetes mellitus (T2DM) or metabolic syndrome (MS).
    Type: Grant
    Filed: May 6, 2020
    Date of Patent: June 14, 2022
    Assignee: ChemoCentryx, Inc.
    Inventors: Zhenhua Miao, Israel Charo
  • Method of Treating Focal Segmental Glomerulosclerosis
    Patent number: 11324736
    Abstract: A method of treating focal segmental glomerulosclerosis with a compound of Formula I is provided. FSGS may be primary (no known cause) or secondary. The secondary FSGS may be associated with infections or viruses such as HIV, diseases such as sickle cell disease or lupus, toxins or drugs such as anabolic steroids, heroin or pamidronate, nephron loss and hyperfiltration, such as with chronic pyelonephritis and reflux, morbid obesity, or diabetes mellitus.
    Type: Grant
    Filed: June 19, 2020
    Date of Patent: May 10, 2022
    Assignee: ChemoCentryx, Inc.
    Inventors: Zhenhua Miao, Thomas Schall, Rajinder Singh
  • Combination therapy using a chemokine receptor 2 (CCR2) antagonist and a PD-1/PD-L1 inhibitor
    Patent number: 11304952
    Abstract: The present disclosure is drawn to the combination therapy of a Chemokine Receptor 2 (CCR2) antagonist and a PD-1 and/or PD-L1 inhibitor in the treatment of cancer.
    Type: Grant
    Filed: September 24, 2018
    Date of Patent: April 19, 2022
    Assignee: ChemoCentryx, Inc.
    Inventors: James J. Campbell, Zhenhua Miao, Thomas J. Schall, Israel Charo, Shijie Li, Christine Marie Janson, Rajinder Singh, Karen Ebsworth
  • Method of treating focal segmental glomerulosclerosis
    Patent number: 10973809
    Abstract: A method of treating focal segmental glomerulosclerosis with a compound of Formula I is provided. FSGS may be primary (no known cause) or secondary. The secondary FSGS may be associated with infections or viruses such as HIV, diseases such as sickle cell disease or lupus, toxins or drugs such as anabolic steroids, heroin or pamidronate, nephron loss and hyperfiltration, such as with chronic pyelonephritis and reflux, morbid obesity, or diabetes mellitus.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: April 13, 2021
    Assignee: ChemoCentryx, Inc.
    Inventors: Zhenhua Miao, Thomas Schall, Rajinder Singh
  • TREATMENT OF FOCAL SEGMENTAL GLOMERULOSCLEROSIS WITH CCR2 ANTAGONISTS
    Publication number: 20210000834
    Abstract: Provided herein are methods of treating focal segmental glomerulosclerosis, said methods include administering to a subject in need thereof a therapeutically effective amount of a CCR2 antagonist. In some embodiments, the CCR2 antagonist is used in monotherapy. In some embodiments, the CCR2 antagonist is used in combination therapy. In some embodiments, the additional therapeutic agent is a RAAS blocker and/or an endothelin receptor inhibitor.
    Type: Application
    Filed: August 11, 2020
    Publication date: January 7, 2021
    Inventors: Zhenhua MIAO, Thomas J. SCHALL, Rajinder SINGH
  • Method of Treating Focal Segmental Glomerulosclerosis
    Publication number: 20200323832
    Abstract: A method of treating focal segmental glomerulosclerosis with a compound of Formula I is provided. FSGS may be primary (no known cause) or secondary. The secondary FSGS may be associated with infections or viruses such as HIV, diseases such as sickle cell disease or lupus, toxins or drugs such as anabolic steroids, heroin or pamidronate, nephron loss and hyperfiltration, such as with chronic pyelonephritis and reflux, morbid obesity, or diabetes mellitus.
    Type: Application
    Filed: June 19, 2020
    Publication date: October 15, 2020
    Inventors: Zhenhua MIAO, Thomas SCHALL, Rajinder SINGH
  • Treatment of focal segmental glomerulosclerosis with CCR2 antagonists
    Patent number: 10758540
    Abstract: Provided herein are methods of treating focal segmental glomerulosclerosis, said methods include administering to a subject in need thereof a therapeutically effective amount of a CCR2 antagonist. In some embodiments, the CCR2 antagonist is used in monotherapy. In some embodiments, the CCR2 antagonist is used in combination therapy. In some embodiments, the additional therapeutic agent is a RAAS blocker and/or an endothelin receptor inhibitor. The CCR2 antagonist may have the structure of formula (I).
    Type: Grant
    Filed: October 10, 2018
    Date of Patent: September 1, 2020
    Assignee: ChemoCentryx, Inc.
    Inventors: Zhenhua Miao, Thomas J. Schall, Rajinder Singh
  • Method of Treating Liver Fibrosis
    Publication number: 20200268727
    Abstract: A method of treating liver fibrosis with CCR2 antagonists is provided. The liver fibrosis may be associated with non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), emerging cirrhosis, non-cirrhotic hepatic fibrosis, type 2 diabetes mellitus (T2DM) or metabolic syndrome (MS).
    Type: Application
    Filed: May 6, 2020
    Publication date: August 27, 2020
    Inventors: Zhenhua Miao, Israel Charo
  • Method of treating liver fibrosis
    Patent number: 10682344
    Abstract: A method of treating liver fibrosis with CCR2 antagonists is provided. The liver fibrosis may be associated with non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), emerging cirrhosis, non-cirrhotic hepatic fibrosis, type 2 diabetes mellitus (T2DM) or metabolic syndrome (MS).
    Type: Grant
    Filed: June 2, 2017
    Date of Patent: June 16, 2020
    Assignee: ChemoCentryx, Inc.
    Inventors: Zhenhua Miao, Israel Charo
  • COMBINATION THERAPY USING A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1/PD-L1 INHIBITOR
    Publication number: 20190275015
    Abstract: The present disclosure is drawn to the combination therapy of a Chemokine Receptor 2 (CCR2) antagonist and a PD-1 and/or PD-L1 inhibitor in the treatment of cancer.
    Type: Application
    Filed: March 19, 2019
    Publication date: September 12, 2019
    Inventors: James J. CAMPBELL, Zhenhua MIAO
  • COMBINATION THERAPY USING A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1/PD-L1 INHIBITOR
    Publication number: 20190134049
    Abstract: The present disclosure is drawn to the combination therapy of a Chemokine Receptor 2 (CCR2) antagonist and a PD-1 and/or PD-L1 inhibitor in the treatment of cancer.
    Type: Application
    Filed: September 24, 2018
    Publication date: May 9, 2019
    Inventors: James J. CAMPBELL, Zhenhua MIAO
  • TREATMENT OF FOCAL SEGMENTAL GLOMERULOSCLEROSIS WITH CCR2 ANTAGONISTS
    Publication number: 20190134042
    Abstract: Provided herein are methods of treating focal segmental glomerulosclerosis, said methods include administering to a subject in need thereof a therapeutically effective amount of a CCR2 antagonist. In some embodiments, the CCR2 antagonist is used in monotherapy. In some embodiments, the CCR2 antagonist is used in combination therapy. In some embodiments, the additional therapeutic agent is a RAAS blocker and/or an endothelin receptor inhibitor.
    Type: Application
    Filed: October 10, 2018
    Publication date: May 9, 2019
    Inventors: Zhenhua MIAO, Thomas J. SCHALL, Rajinder SINGH
  • METHOD OF TREATING FOCAL SEGMENTAL GLOMERULOSCLEROSIS
    Publication number: 20180140587
    Abstract: A method of treating focal segmental glomerulosclerosis with a compound of Formula I is provided. FSGS may be primary (no known cause) or secondary. The secondary FSGS may be associated with infections or viruses such as HIV, diseases such as sickle cell disease or lupus, toxins or drugs such as anabolic steroids, heroin or pamidronate, nephron loss and hyperfiltration, such as with chronic pyelonephritis and reflux, morbid obesity, or diabetes mellitus.
    Type: Application
    Filed: November 22, 2017
    Publication date: May 24, 2018
    Inventors: Zhenhua Miao, Thomas Schall, Rajinder Singh
  • METHOD OF TREATING LIVER FIBROSIS
    Publication number: 20170348293
    Abstract: A method of treating liver fibrosis with CCR2 antagonists is provided. The liver fibrosis may be associated with non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), emerging cirrhosis, non-cirrhotic hepatic fibrosis, type 2 diabetes mellitus (T2DM) or metabolic syndrome (MS).
    Type: Application
    Filed: June 2, 2017
    Publication date: December 7, 2017
    Inventors: Zhenhua Miao, Israel Charo